Tesamorelin 5 sizes RESEARCH USE ONLY BLACK BOX BIOTECHNOLOGY · TSM2

Tesamorelin

Also known as: TH9507 · Egrifta · GHRH (1-44) analogue
Growth Hormone Axis In stock Box of 10 vials 1 reference

Stabilised GHRH analogue with phase 3 evidence for visceral-fat reduction.

Available sizes

SKUPer vialPack
TSM2 2 mg 10 vials / box
TSM5 5 mg 10 vials / box
TSM10 10 mg 10 vials / box
TSM15 15 mg 10 vials / box
TSM20 20 mg 10 vials / box

Order Tesamorelin

Pricing is quoted directly and is competitive at every tier — message us with the SKUs you want and quantities for a quote.

Quote on Telegram Quote on Signal

Replies within 36 hours. Cryptocurrency (preferred) or card / money-app with a processing fee. COA for this batch available on request.

Tesamorelin is a synthetic analogue of human growth-hormone-releasing hormone (GHRH 1-44) with a trans-3-hexenoic acid group on the N-terminus that protects it from dipeptidyl-peptidase cleavage. It stimulates pulsatile, physiological GH release from the pituitary.

In a 26-week phase 3 trial in HIV-associated lipodystrophy (n = 412), tesamorelin reduced visceral adipose tissue by 15.2% versus a 5.0% increase with placebo, with corresponding increases in IGF-1 and improvements in triglycerides 1.

At a glance

  • DPP-4-resistant GHRH analogue; FDA-approved reference compound
  • Phase 3 visceral-fat data in NEJM
  • Five sizes from 2 mg to 20 mg; also blended with ipamorelin
Research use only. All products are sold strictly for laboratory research and development purposes. They are not intended for human or veterinary use, diagnosis, treatment, cure or prevention of any disease. Not for human consumption. Summaries above describe published findings in laboratory and clinical research models and do not constitute claims about this product.
Form
Lyophilized powder
Purity
HPLC-verified — Certificate of Analysis available on request
Pack size
Box of 10 vials
Storage
Lyophilized: −20 °C, protected from light (2–8 °C short-term). Reconstituted: 2–8 °C.
Formula
C221H366N72O67S
Mol. weight
5135.9 g/mol
CAS No.
218949-48-5

Sequence, formula and CAS data are provided for identification. Batch-specific purity, mass-spec and HPLC data are on the Certificate of Analysis — ask for it with your order.

  1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.

Citations retrieved from PubMed (NCBI). Links open the publisher record via DOI and the PubMed abstract.

Related

Often ordered together

More in GH Axis
Quote on Telegram